Mitraciliatine: Mixed Opioid Pharmacology, Human Exposure & Evidence Gaps

What is mitraciliatine?

Mitraciliatine is a minor indole alkaloid isolated from kratom and a stereochemical relative of mitragynine. It is distinct from speciociliatine despite the similar names. Primary pharmacology research treats it as its own molecular entity, with activity that cannot be replaced by a generic description of kratom or 7-OH. Minor-alkaloid study

Safety boundary: This page does not establish a safe consumer dose, recommend isolated mitraciliatine, or offer withdrawal self-treatment. Read the medical disclaimer.

Human evidence

A small healthy-adult pharmacokinetic study measured mitraciliatine after mixed kratom tea. It demonstrates exposure in that mixture setting, rather than efficacy or safety of an isolated mitraciliatine preparation. The study cannot attribute a clinical response to mitraciliatine independently of the other alkaloids. Human PK study

No controlled isolated-mitraciliatine therapeutic trial was identified in the sources reviewed. A human receptor experiment is also not human clinical evidence: it studies a receptor in a laboratory system. The distinction prevents a technically accurate reference to “human MOR” from suggesting that patients were treated or a benefit was measured.

Preclinical evidence

The 2021 minor-alkaloid study investigated receptor signaling and mouse behavior. Its mitraciliatine experiments describe mixed opioid pharmacology, including antinociception and respiratory measurements in experimental animals. These findings make it a research probe; they do not establish treatment of pain or an overdose-safety advantage in people. Primary experiments

Animal respiratory observations must retain the species, exposure, and assay boundary. They cannot be converted into a claim that a consumer product prevents respiratory depression, particularly when product identity and co-exposures differ from the experiment. No human potency-conversion chart follows from these results.

Pharmacology and receptors

The 2021 experiments reported MOR partial agonism in mouse-receptor assays and KOR agonism. A 2026 study characterized mitraciliatine as a MOR antagonist/KOR agonist at human receptors. Species and assay differences matter: a single unqualified “mu agonist” label would erase the newer finding. 2021 · 2026

An antagonist blocks a reference agonist's response under the tested conditions; it is not automatically an antidote. KOR activation likewise does not establish a useful psychiatric or analgesic outcome. These laboratory properties need to be separated from clinical claims about euphoria, dysphoria, dependence, withdrawal treatment, or respiratory protection.

Metabolism and pharmacokinetics

Human exposure measurements after kratom tea are available, but the reviewed evidence does not establish isolated-compound oral bioavailability, metabolic contributions, or repeated-use accumulation. It also does not establish which metabolites account for any pharmacological effect in humans. Tea PK study

Mitragynine's conversion to 7-OH should not be assigned to mitraciliatine merely because the molecules are related. Reliable PK interpretation requires a compound-specific analytical method and a defined product. An onset, duration, or dosing interval suitable for consumer use cannot be supplied from the mixture study.

Safety

Long-term cardiopulmonary, reproductive, developmental, and organ safety is unestablished for isolated mitraciliatine in the reviewed literature. A signaling-bias result or a favorable mouse respiratory observation cannot close that gap. FDA's broader kratom warnings are product-level context and do not identify mitraciliatine as the cause of a particular adverse event. FDA

Dependence and withdrawal

The evidence reviewed does not quantify human dependence or withdrawal from isolated mitraciliatine. Mixed-product kratom reports cannot identify its individual contribution. Mixed receptor activity also does not prove that repeated use is non-addictive or that this compound treats withdrawal from another opioid. Those claims require direct evidence of the relevant human outcome.

Interactions

The receptor experiments raise questions about co-exposure to other opioid-active substances, but they do not establish a clinical combination regimen or a protective interaction. In particular, laboratory MOR antagonism does not make mitraciliatine a substitute for emergency treatment. Compound-specific clinical interaction studies are missing from the sources reviewed, leaving the magnitude and direction of real-world effects unresolved.

Regulatory status — September 30, 2026

FDA has not approved kratom for medical use. That product-level position does not establish an approved indication for mitraciliatine. This review provides no comprehensive legal determination for the isolated alkaloid; rules for botanical material and for particular derivatives must be assessed separately. Online sale is not evidence of legal clearance or clinical safety. FDA

Evidence gaps

Priorities are independent reconciliation of human/mouse receptor results, isolated-compound PK, controlled safety studies, and direct clinical assessment of interactions and repeated exposure. The present evidence supports a distinct experimental alkaloid with mixed receptor activity, while leaving therapeutic benefit and consumer safety unresolved.

Related compounds

• Mitragynine: the main alkaloid and human-evidence anchor.
• Speciociliatine and speciogynine: separate stereochemical relatives.
• 7-Hydroxymitragynine and mitragynine pseudoindoxyl: derivatives with separate dependence and safety evidence.
• 3-Dehydromitragynine: a distinct metabolism/toxicology question.

Explore the substance-use evidence hub for broader clinical context. Primary references and identifiers are listed below.